Status:

COMPLETED

Parecoxib for Pain Management After Total Knee Arthroplasty and Total Hip Arthroplasty

Lead Sponsor:

Peking Union Medical College Hospital

Conditions:

Pain, Postoperative

Eligibility:

All Genders

18-65 years

Phase:

PHASE4

Brief Summary

Evaluated the effect of perioperative parecoxib administration on postoperative pain, analgesic use, function recovery, inflammatory response and bleeding risk.

Detailed Description

Non-steroid anti-inflammatory drugs are recommended for multimodal postoperative pain management. We evaluated the effect of perioperative parecoxib administration on postoperative pain, analgesic us...

Eligibility Criteria

Inclusion

  • Male or female patients who have underwent primary unilateral total knee arthroplasty (TKA) and total hip arthroplasty (THA).
  • Age between 18-65 years.
  • Chinese ethnicity.

Exclusion

  • patients who underwent a reversion or a previous TKA or THA, emergency TKA, or TKA as result of a trauma.
  • patient exhibited allergy to parecoxib sodium.
  • lactating or pregnant.
  • any other conditions not suitable for surgery as evaluated by the surgeon in charge.

Key Trial Info

Start Date :

October 1 2014

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

August 1 2015

Estimated Enrollment :

74 Patients enrolled

Trial Details

Trial ID

NCT02272660

Start Date

October 1 2014

End Date

August 1 2015

Last Update

August 28 2015

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

The Peking Union Medical College Hospital

Beijing, Beijing Municipality, China, 100005